Table 6 Results of four network meta-analyses: based on only aggregate data; combining IPD and aggregate data with no covariate adjustments; combining IPD and aggregate data with covariate adjustments for individual patient AGE, baseline STATUS and baseline PVR at within-study level; using the covariate adjusted IPD and aggregate data model with the observational studies down-weighted by inflating their standard errors by a factor of 10; using the covariate adjusted IPD and aggregate data model with constructed control arms for observational studies with an assumed deterioration of 25 meters in 6MWD
Model | M1 | M2 | M3 | S1 | S2 |
|---|---|---|---|---|---|
Model description | Aggregate data only | IPD and aggregate with no covariate adjustments | IPD and aggregate with covariate adjustments | Down-weighted observational studies | Constructed control arms |
α i , Jacobs 2009 | 4.77 (-18.60,29.12) | 4.55 (-19.07, 29.45) | 4.39 (-18.77, 28.59) | 4.07 (-17.16, 26.84) | −1.10 (-22.54, 17.77) |
α i , (imatinib to ERA + PDE5i) | 4.27 (-14.13, 22.59) | 3.63 (-10.57, 17.78) | 3.50 (-10.59, 17.69) | 3.55 (-9.78, 17.12) | 0.93 (-11.93, 14.71) |
α (mean of α i s) | 4.78 (-4.77, 14.60) | 4.39 (-5.14, 14.80) | 4.30 (-4.73, 14.17) | 3.99 (-4.87, 13.68) | 0.02 (-8.74, 8.78) |
π 1 (AGE) | NA | NA | −0.90 (-1.52, -0.27) | −0.90 (-1.52, -0.27) | −0.89 (-1.53, -0.26) |
π 3 (STATUS) | NA | NA | −11.89 (-28.20, 4.44) | −11.92 (-28.29, 4.36) | −12.02 (-28.64, 4.60) |
π 5 (PVR) | NA | NA | −0.05 (-0.70, -0.02) | −0.05 (-0.07, -0.02) | −0.05 (-0.07, -0.02) |
β 6 (Pr to ERA + PDE5i) | 35.98 (-44.15, 114.70) | 35.16 (-43.81, 113.80) | 34.65 (-42.18, 113.20) | 22.64 (-168.30, 217.00) | 40.65 (-37.09, 117.80) |
β 8 (imatinib to ERA + PDE5i) | 39.09 (2.72, 75.80) | 39.91 (11.31, 68.36) | 40.06 (13.38, 67.67) | 39.40 (13.83, 66.03) | 42.62 (15.18, 69.79) |
(β 8  − β 6 ) imatinib v Pr to ERA + PDE5i | 3.11 (-83.70, 89.27) | 4.75 (-77.88, 87.10) | 5.41 (-76.65, 85.24) | 16.76 (-179.26, 209.80) | 1.97 (-78.62, 83.53) |